Document is current
Any future updates will be listed below
-
Authors
Cortesi, Paolo A.
Mezghani, Marwa
Alshaikheid, Mohammed
Lunk, Izabella
D’Orsi, Mario Fazzi
Zurria, Monica
Bandello, Francesco
-
Funding
Funding for this research was provided by:
Bayer Consumer Care AG
- License Information
-
More Information
Article History
Received: 16 January 2026
Accepted: 26 February 2026
First Online: 28 March 2026
Declarations
:
: Prof. Francesco Bandello consults for Abbvie, Adverum Biotechnologies Inc., Alimera, Apellis, Bayer, Boehringer Ingelheim, Breye Therapeutics A.p.S., Fidia Sooft, Hoffmann-La Roche, Outlook Therapeutics, Novartis, NTC Pharma, Oxurion NV, 4D Molecular Therapeutics Inc., SIFI. Prof. Paolo Angelo Cortesi has received grants and personal fees from Hoffmann-La Roche, Almirall, Otsuka, Novartis, Daiichi Sankyo, Boehringer Ingelheim, and Bayer. Izabella Lunk, Mario Fazzi D’Orsi, and Monica Zurria are employees of Bayer. Marwa Mezghani and Mohammed Alshaikheid declare that they were employed by Putnam at the time the research was conducted, a company which received funds from Bayer to conduct this research.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
